MedTrace Logo

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

NCT06889610 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-11-21

No results posted yet for this study

Summary

This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.

Conditions

  • Triple Negative Breast Cancer Metastatic
  • Melanoma Metastatic
  • Colorectal Cancer Metastatic

Interventions

COMBINATION_PRODUCT

MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer

Multimodal ablation combined with pucotenlimab and TPC or sacituzumab govitecan, eribulin,gemcitabine,UTD1

COMBINATION_PRODUCT

MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer

Multimodal ablation combined with cadonilimab and fruquintinib

COMBINATION_PRODUCT

MTT(Multimodal Tumor Thermal Therapy System)- Melanoma

Multimodal ablation combined with pucotenlimab, with other specific agents determined based on the first-line treatment regimen and the melanoma subtype.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Hongxia Wang, MD · Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-04
Primary Completion
2027-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06889610 on ClinicalTrials.gov